FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to radiology and nephrology, and can be applied for prevention of contrast-induced nephropathy before carrying out radio-opaque examination. For this purpose introduced is cytoflavin in dose 1 pill 3 times per day 2-5 days before carrying out radio-opaque examination.
EFFECT: method makes it possible to protect cells of renal channels from toxic action of radio-opaque combination due to improvement of energy processes in cells and tissues by regulation of two most important stages of Krebs cycle: including pyruvic acid and its oxidation to acetyl CoA, as well as oxidative decarboxylation of a-ketoglutaric acid, which results in reduction of depression of activity of succinate dehydrogenase of peripheral blood lymphocytes.
2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ASSESSING THE RISK OF CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH ACUTE MYOCARDICAL INFARCTION WHO UNDERWENT CORONARY ANGIOGRAPHY AND PERCUTANEOUS CORONARY INTERVENTION | 2020 |
|
RU2742162C1 |
| METHOD OF ESTIMATING NEPHROTOXIC IMPACT OF ROENTGENOPAQUE PREPARATIONS | 2007 |
|
RU2354404C2 |
| DIAGNOSTIC TECHNIQUE FOR RENAL PARENCHYMAL INJURY IN CHILDREN | 2011 |
|
RU2452959C1 |
| DIGITAL SUBTRACTION ANGIOGRAPHY METHOD FOR TREATING PERIPHERAL ATHEROSCLEROSIS | 2022 |
|
RU2814478C2 |
| METHOD FOR DETERMINATION OF DEGREE OF RENAL PARENCHYMA DAMAGE IN CHILDREN WITH VESICOURETERIC REFLUX | 2011 |
|
RU2442990C1 |
| METHOD FOR DIAGNOSING REFLUX NEPHROPATHY | 2003 |
|
RU2239838C1 |
| METHOD FOR ASSESSING RENAL VIABILITY BY ULTRASONIC EXAMINATION WITH ECHO CONTRAST IN THE EARLY POSTOPERATIVE PERIOD IN ANURIA AFTER EXTRACORPOREAL NEPHRECTOMY IN THE CONDITIONS OF PHARMACO-COLD ISCHEMIA WITHOUT CROSSING THE URETER WITH ORTHOTOPIC VESSEL REPLANTATION | 2019 |
|
RU2686914C1 |
| METHOD OF TREATING IgA-NEPHROPATHY | 2010 |
|
RU2445080C1 |
| METHOD OF ESTIMATING PROCESS ACTIVITY IN NEPHRITIS PATIENT WITH PRESERVED KIDNEY FUNCTION | 2002 |
|
RU2214603C1 |
| METHOD OF PREDICTION RISK OF ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS FOR 6 YEARS AFTER SCHEDULED ENDOVASCULAR MYOCARDIUM REVASCULARIZATION | 2017 |
|
RU2642930C1 |
